Screener
Royalty Pharma RPRX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net income attributable to non-controlling interests | 63,603 | 60,459 | 237,169 | 255,543 |
| Net income attributable to Royalty Pharma plc | $17,883 | $32,176 | $312,572 | $271,525 |
| Earnings per Class A ordinary share: | ||||
| Basic | $0.04 | $0.08 | $0.71 | $0.63 |
| Diluted | $0.04 | $0.07 | $0.71 | $0.63 |
| Weighted average Class A ordinary shares outstanding: | ||||
| Basic | 445,064 | 423,514 | 440,950 | 429,464 |
| Diluted | 556,896 | 562,298 | 557,352 | 570,157 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's shares (diluted)?
- Royalty Pharma (RPRX) reported shares (diluted) of 556.9M in Q2 2026.
- How has Royalty Pharma's shares (diluted) changed year-over-year?
- Royalty Pharma's shares (diluted) decreased by 1.0% year-over-year, from 562.3M to 556.9M.
- What is the long-term trend for Royalty Pharma's shares (diluted)?
- Over 4 years (2021 to 2025), Royalty Pharma's shares (diluted) has grown at a 0.3% compound annual growth rate (CAGR), from 2.2B to 2.3B.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Royalty Pharma's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude